Skip to main content

Leadership

2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
DateTitle  
12/12/17Emergent BioSolutions Awarded Department of National Defence Contract to Supply Anthrasil to the Canadian GovernmentDownload PDFPrinter Friendly Version
11/30/17Emergent BioSolutions to Host 2017 Analyst & Investor DayDownload PDFPrinter Friendly Version
11/20/17Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts FacilityDownload PDFPrinter Friendly Version
11/14/17Emergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Senior Notes Due 2021Download PDFPrinter Friendly Version
11/02/17Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 GuidanceDownload PDFPrinter Friendly Version
10/19/17Emergent BioSolutions to Release Third Quarter and Nine Months 2017 Financial Results and Conduct a Conference Call on November 2, 2017Download PDFPrinter Friendly Version
10/06/17Emergent BioSolutions Completes Acquisition of ACAM2000® Business From SanofiDownload PDFPrinter Friendly Version
10/04/17Emergent BioSolutions Awarded U.S. Department of State Contract Valued at Up to $25 Million to Supply Nerve Agent Antidote Auto-InjectorDownload PDFPrinter Friendly Version
10/03/17Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSKDownload PDFPrinter Friendly Version
10/02/17Emergent BioSolutions Announces Closing of New $200 Million Senior Secured Credit FacilityDownload PDFPrinter Friendly Version
09/25/17Emergent BioSolutions to Supply DoD With Chemical Threat Countermeasure RSDL Under Five-Year Follow-On Contract Valued at Up to $171 MillionDownload PDFPrinter Friendly Version
09/18/17Emergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide ExposureDownload PDFPrinter Friendly Version
08/03/17Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 GuidanceDownload PDFPrinter Friendly Version
07/31/17Emergent BioSolutions Awarded $23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of DefenseDownload PDFPrinter Friendly Version
07/26/17Emergent BioSolutions Secures Exclusive Worldwide Rights to Valneva’s Zika Vaccine TechnologyDownload PDFPrinter Friendly Version
07/20/17Emergent BioSolutions to Release Second Quarter 2017 Financial Results and Conduct a Conference Call on August 3, 2017Download PDFPrinter Friendly Version
07/19/17Emergent BioSolutions to Acquire Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSKDownload PDFPrinter Friendly Version
07/14/17Emergent BioSolutions to Acquire ACAM2000® Business From SanofiDownload PDFPrinter Friendly Version
05/11/17Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 25, 2017 at 9:00 AM EDT; Webcast Will be AvailableDownload PDFPrinter Friendly Version
05/10/17Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in BaltimoreDownload PDFPrinter Friendly Version
05/09/17Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDADownload PDFPrinter Friendly Version
05/04/17Emergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 GuidanceDownload PDFPrinter Friendly Version
04/20/17Emergent BioSolutions to Release First Quarter 2017 Financial Results and Conduct a Conference Call on May 4, 2017Download PDFPrinter Friendly Version
03/31/17Emergent BioSolutions Signs $53 Million Modification to BARDA Contract for the Manufacture of Botulism AntitoxinDownload PDFPrinter Friendly Version
03/17/17Emergent BioSolutions Awarded $100 Million BARDA Contract for BioThrax Deliveries to the Strategic National StockpileDownload PDFPrinter Friendly Version
02/23/17Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2016 Financial Results; Reaffirms 2017 Guidance and Provides 2020 GoalsDownload PDFPrinter Friendly Version
02/13/17Emergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemorrhagic Fever TherapeuticsDownload PDFPrinter Friendly Version
02/09/17Emergent BioSolutions to Release Fourth Quarter and Full Year 2016 Financial Results and Conduct a Conference Call on February 23, 2017Download PDFPrinter Friendly Version
02/01/17Emergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study to Evaluate Broad-Spectrum Antiviral UV-4B for DengueDownload PDFPrinter Friendly Version
01/27/17Emergent BioSolutions Receives German Federal Ministry of Health Approval of Building 55 for Large-Scale Manufacturing of BioThraxDownload PDFPrinter Friendly Version
01/09/17Emergent BioSolutions Announces Preliminary 2016 Financial Results and Provides 2017 Financial OutlookDownload PDFPrinter Friendly Version